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Abstract
 
Chemoattractants and chemokines induce arrest of rolling monocytes during emigration from
blood into tissues. In this study, we demonstrated that 
 
a
 
4 integrin affinity for vascular cell adhe-
sion molecule (VCAM)-1 was upregulated rapidly and transiently by chemoattractants and stro-
mal cell–derived factor (SDF)-1
 
a
 
 and mediated monocyte arrest. 
 
a
 
4 integrin affinity changes
were detected and blocked using soluble VCAM-1/Fc (sVCAM-1/Fc). In a flow cytometry as-
say, markedly increased sVCAM-1/Fc binding to human blood monocytes or U937 cells trans-
fected with formyl peptide (FP) receptor was detected 30 s after FP or SDF-1
 
a 
 
treatment and
declined after 2 min. In a parallel plate flow chamber assay, FP, C5a, platelet-activating factor,
or SDF-1
 
a 
 
coimmobilized with VCAM-1 induced leukocyte arrest, which was blocked by in-
clusion of sVCAM-1/Fc but not soluble nonimmune immunoglobulin G in the assay buffer.
 
Key words: stromal cell–derived factor
 
 
 
1
 
a
 
 • chemokines • formyl peptide • very late antigen 4 • 
inﬂammation
 
Introduction
 
The emigration of leukocytes from blood into normal and
inflamed tissues is a sequential multistep process (1, 2).
Transient adhesive interactions between selectins and their
carbohydrate ligands mediate tethering and rolling of leu-
kocytes along vascular endothelium (3). Rolling slows leu-
kocytes relative to blood flow and facilitates exposure to
chemokines and chemoattractants presented by proteogly-
cans on the endothelial surface at inflammatory sites (4, 5).
Chemokine signaling through G protein–coupled receptors
triggers leukocyte arrest via 
 
b
 
2 and 
 
a
 
4 integrin binding to
intercellular adhesion molecule (ICAM)
 
1
 
-1 and vascular
cell adhesion molecule (VCAM)-1, respectively (6–9).
Subsequently, leukocytes undergo cytoskeletal rearrange-
ment, extend processes to endothelial cell junctions, and
diapedese through the endothelial monolayer.
Although leukocyte 
 
b
 
2 and 
 
a
 
4 integrins are expressed
constitutively by circulating leukocytes, they have low
ligand-binding activity (10) and do not mediate the stable
adhesive interactions necessary for arrest, firm adhesion,
and diapedesis. To undergo these steps, leukocytes must
upregulate either integrin affinity or avidity in response to
stimulation by a wide array of receptors and signaling path-
ways. Conformational changes affecting molecular struc-
ture and kinetic properties of individual bonds account for
increased integrin affinity, whereas alignment and/or clus-
tering of multiple receptor ligand pairs is the mechanism of
high avidity–mediated adhesion (11, 12). Soluble ligands
bind high affinity integrins (13, 14) and can be used to in-
hibit high affinity but not high avidity adhesion (12, 13).
Also, conformation-specific monoclonal antibodies may
recognize neoepitopes present on high affinity integrins
(15–17), although it is possible that they also recognize in-
tegrins stabilized by bound ligand (18–20). Affinity modu-
lation as detected by either soluble ligand binding or
neoepitope expression has been well-characterized for the
platelet integrin 
 
a
 
IIb
 
b
 
3 (21) and is also apparent for leuko-
cyte 
 
b
 
2 and 
 
a
 
4 integrins (11, 12, 14).
VCAM-1–
 
a
 
4 integrin adhesive interactions can mediate
all steps of leukocyte emigration from rolling to diapedesis.
Peripheral blood lymphocytes and monocytes generally ex-
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Abbreviations used in this paper:
 
 CXCR, CXC chemokine receptor;
cytD, cytochalasin D; FBS, fetal bovine serum; FP, formyl peptide;
ICAM, intercellular adhesion molecule; MCP, monocyte chemotactic
protein; PAF, platelet-activating factor; PTx, pertussis toxin; RANTES,
regulated upon activation, normal T cell expressed and secreted; SDF,
stromal cell–derived factor; VCAM, vascular cell adhesion molecule. 
1150
 
a
 
4 Integrin Affinity Upregulation Mediates Arrest
 
press low affinity integrins and roll on VCAM-1 (22–24).
In contrast, Jurkat T cells express predominantly high affin-
ity 
 
a
 
4 integrins and do not roll but arrest in VCAM-1–
coated flow chambers (25). These data suggest that low af-
finity 
 
a
 
4 integrins mediate rolling, a process that involves
transient adhesive interactions, whereas high affinity 
 
a
 
4 in-
tegrins mediate arrest. Our data are consistent with this and
demonstrate that monocytes rapidly upregulate 
 
a
 
4 integrin
affinity for VCAM-1 and arrest upon encountering a
chemoattractant or stromal cell–derived factor (SDF)-1
 
a
 
.
 
Materials and Methods
 
Reagents.
 
Recombinant human VCAM-1/Fc chimera was
obtained from D. Staunton (ICOS Corp., Bothwell, WA) and
consisted of seven or five NH
 
2
 
-terminal extracellular Ig-like do-
mains of VCAM-1 linked to the Fc portion of human IgG
 
1
 
. Both
forms contained two 
 
a
 
4 integrin ligand–binding sites and had
comparable activity. The longer, seven-domain form was immo-
bilized on plates for parallel plate flow chamber adhesion assays,
whereas the five-domain form was used in solution for blockade
and detection of high affinity 
 
a
 
4 integrins. Recombinant hu-
man SDF-1
 
a
 
, monocyte chemotactic protein (MCP)-1, regu-
lated upon activation, normal T cell expressed and secreted
(RANTES), inflammatory protein (IP)-10, I-309, and Gro-
 
a
 
(Peprotech), fluorescein-labeled formyl peptide (FP) formyl-Nle-
Leu-Phe-Nle-Tyr-Lys (fNLP-FITC; Molecular Probes), recom-
binant human C5a (Sigma-Aldrich), and platelet-activating factor
(PAF) as well as its antagonist (Calbiochem) were purchased. Pri-
mary antibodies included mouse anti–human CD49d (clone
HP2/1; Serotec), rabbit antifluorescein (Molecular Probes), rabbit
anti–human SDF-1
 
a 
 
(Peprotech), mouse anti–human CXC che-
mokine receptor (CXCR)4 (clone 48607.121; R&D Systems),
and mouse anti–human CD3 (clone UCHT-1; Chemicon Inter-
national). F(ab
 
9
 
)
 
2
 
 fragments of goat anti–human IgG (Fc specific)
and goat anti–rabbit IgG (Fc specific) were from Caltag. Second-
ary antibodies for flow cytometry included PE-conjugated F(ab
 
9
 
)
 
2
 
fragments of goat anti–human IgG and FITC-conjugated goat
anti–mouse IgG (Jackson ImmunoResearch Laboratories). Other
reagents included manganese chloride, nonimmune human IgG
 
1
 
,
FP (fMLP) and pertussis toxin (PTx) (Sigma-Aldrich), cytochala-
sin D (cytD) and latrunculin B (Calbiochem), and Oregon green–
conjugated phalloidin (Molecular Probes).
 
Cell Culture and Peripheral Blood Mononuclear Cell Isolation.
 
U937 cells, a monocytoid cell line, transfected with human FP
receptor (U937-FPR) or vector (U937-vector) were obtained
from Dr. Gregory P. Downey (University of Toronto, Toronto,
Canada). These lines expressed equivalent levels of 
 
a
 
4 and 
 
b
 
1 in-
tegrins, and CXCR4, the SDF-1
 
a 
 
receptor (determined by flow
cytometry, and data not shown). U937 cells were cultured in
RPMI 1640 (GIBCO BRL) supplemented with 10% heat-inacti-
vated fetal bovine serum (FBS; GIBCO BRL) and 500 
 
m
 
g/ml
geneticin (GIBCO BRL). Human peripheral blood mononuclear
leukocytes were isolated by density gradient centrifugation.
Venous blood anticoagulated with heparin or EDTA was ob-
tained from healthy volunteers, and the buffy coat was layered
over Histopaque 1077 (Sigma-Aldrich), and centrifuged at 300 
 
g
 
to obtain mononuclear leukocytes. Leukocytes were resuspended
in RPMI 1640 supplemented with 5% heat-inactivated autolo-
gous plasma and used immediately. Monocytes were purified
from mononuclear leukocytes by negative depletion using a mag-
netic particle kit with specific antibodies to T and B lymphocytes,
 
NK cells, and granulocytes (Miltenyi Biotec). Purified monocytes
were suspended in RPMI 1640, 5% heat-inactivated autologous
plasma (10
 
8
 
C), and used within 1 h.
 
Detection of High Affinity 
 
a
 
4
 
b
 
1 Integrins by Flow Cytometry.
 
Leukocytes suspended in 700 
 
m
 
l of assay buffer (HBSS containing
1 mM Mg
 
2
 
1
 
/Ca
 
2
 
1
 
, 20 mM Hepes, and 0.5% FBS) at a concen-
tration of 10
 
6
 
 cells/ml were incubated at 37
 
8
 
C with 20 
 
m
 
g/ml
soluble VCAM-1/Fc (sVCAM-1/Fc) or 20 
 
m
 
g/ml nonimmune
human IgG. Preliminary experiments indicated that at least 100
 
m
 
g/ml sVCAM-1/Fc was required to saturate high affinity 
 
a
 
4
 
b
 
1
integrins with 50% saturation binding occurring at 
 
z
 
10 
 
m
 
g/ml
(unpublished data). For practical reasons, all experiments used 20
 
m
 
g/ml sVCAM-1/Fc. Leukocytes were stimulated with 100
nmol/liter FP or 200 ng/ml SDF-1
 
a
 
. At sequential time points,
100-
 
m
 
l aliquots were removed, diluted with 3 ml HBSS, and im-
mediately fixed by adding 0.5 ml of 4% paraformaldehyde at
22
 
8
 
C. Binding of sVCAM-1/Fc was detected with PE-conju-
gated goat anti–human IgG (1:300 dilution for 30 min at 4
 
8
 
C).
Binding of nonimmune IgG and/or pretreatment with 
 
a
 
4 inte-
grin function-blocking antibody HP2/1 (10 
 
m
 
g/ml for 5 min)
was a control for specific VCAM-1/Fc binding. As a positive
control for high affinity 
 
a
 
4 integrin, 0.5 mM MnCl
 
2 
 
was added
to the assay buffer. Flow cytometry was carried out on all samples
immediately after the final wash using an Epics
 
®
 
XL-MCL flow
cytometer (Beckman Coulter).
When peripheral blood mononuclear leukocytes were used, T
cells were identified using anti-CD3 monoclonal antibody and
FITC-labeled goat anti–mouse secondary antibody. Monocytes
were identified by their characteristic forward and side scatter
properties, which correlated with CD14 expression (data not
shown). For each experiment, data were expressed as the per-
centage of sVCAM-1/Fc binding induced by FP or SDF-1
 
a 
 
rela-
tive to the positive control (0.5 mM MnCl
 
2
 
 treatment) because
background binding of PE-conjugated goat anti–human IgG var-
ied between CD3
 
2 
 
cells, CD3
 
1
 
 cells, and monocytes. When
whole blood (50 
 
m
 
l per sample) was used, monocytes were iden-
tified using FITC-labeled anti-CD14 and red blood cells were
lysed with ammonium chloride before analysis. In these experi-
ments, data were expressed relative to binding of a control
protein (nonimmune IgG) for each treatment.
 
Immobilization of VCAM-1, Chemokines, and Chemoattrac-
tants.
 
VCAM-1/Fc, FP (fNLP-FITC), and SDF-1
 
a 
 
were im-
mobilized on plastic according to a protocol described previously
(26) with the following modifications. Goat anti–human IgG and
goat anti–rabbit IgG (Fc specific) F(ab
 
9
 
)
 
2
 
 were passively adsorbed
onto the center of a 35-mm polystyrene tissue culture dish by in-
cubating a 10-
 
m
 
l drop (5 
 
m
 
l each at 100 
 
m
 
g/ml) for 60 min in a
humidified atmosphere (22
 
8
 
C). Dishes were washed with PBS
and nonspecific binding sites were blocked with 5% FBS (60 min
at 22
 
8
 
C). The anti-Fc–coated area was then incubated with a sat-
urating concentration of VCAM-1/Fc plus antifluorescein or
anti–SDF-1
 
a 
 
(10 
 
m
 
l-drop, total concentration 20 
 
m
 
g/ml over-
night at 4
 
8
 
C). In some experiments, the density of immobilized
VCAM-1/Fc was modulated by adjusting the relative molarity
with nonimmune human IgG. At least 1 h before use, dishes
were washed with PBS and incubated with a 10-
 
m
 
l drop of
fNLP-FITC or SDF-1
 
a 
 
(both at 20 
 
m
 
g/ml).
Coimmobilization of other chemoattractants (C5a and PAF)
and chemokines (MCP-1, RANTES, IP-10, I-309, and Gro-
 
a
 
)
was performed as above with the following modifications. Goat
anti–human IgG F(ab
 
9
 
)
 
2
 
 was incubated at 5 
 
m
 
g/ml (60 min at
22
 
8
 
C) followed by chemoattractant or chemokine at 20 
 
m
 
g/ml
(120 min at 22
 
8
 
C). Nonspecific binding sites were blocked with 
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5% FBS, and the area coated with anti-human Fc was incubated
with VCAM-1/Fc at 10 
 
m
 
g/ml for 60 min before use.
 
Parallel Plate Flow Chamber Assays.
 
Cell detachment and ac-
cumulation assays were performed using a parallel plate flow
chamber purchased from Glycotech, Inc. as described previously.
In brief, for detachment assays U937-FPR cells were resuspended
in assay buffer at a concentration of 1.2
 
 3 
 
10
 
6
 
 cells/ml and in-
jected via the outflow port into inverted flow chambers main-
tained at 37
 
8
 
C. Chambers were then overturned and U937-FPR
cells settled for the indicated time period under static conditions.
Shear stress was applied by pulling assay buffer through chambers
for consecutive 30-s intervals (4 and 10 dyn/cm
 
2
 
) with a Genie
programmable syringe pump (Kent Scientific Corp.). Cells were
observed in six microscope fields spanning the entire diameter of
the adhesion molecule–coated area for each level of shear with a
Diaphot 300 inverted phase–contrast microscope (Nikon). All
experiments were videotaped with a Sony DXC-151A color
video camera and Sony SVT-S3100 time-lapse video cassette
recorder for offline analysis with NIH Image (www.ncbi.
nlm.nih.gov). In some experiments, cells were pretreated with 10
 
m
 
g/ml monoclonal antibody HP2/1, 15 min at room tempera-
ture, or 100 ng/ml PTx for 6 h at 37
 
8
 
C.
For accumulation assays, U937-FPR cells (1.0 
 
3 
 
10
 
6
 
 cells/ml)
or purified monocytes (0.5 
 
3
 
 10
 
6
 
 cells/ml) were injected into the
flow chamber at 0.75, 1.0, or 1.5 dyn/cm
 
2
 
, and the number of
accumulated cells in six independent fields was counted after 120 s.
Cells were defined as arrested and accumulated if they remained
stationary over a 2-s interval. For blockade of high affinity 
 
a
 
4
 
b
 
1
integrins, cells were first treated with 20 
 
m
 
g/ml nonimmune hu-
man IgG to block Fc receptors followed by incubation with 20
 
mg/ml sVCAM-1/Fc just before introduction into the flow
chamber. Some cells were perfused in the presence of 0.5 mM
MnCl2 as a positive control.
Actin Polymerization Assay. Actin polymerization induced by
chemoattractants and chemokines was measured as described pre-
viously (27). U937-FPR cells or purified peripheral blood mono-
cytes were resuspended in 200 ml assay buffer at a concentration
of 105 cells/ml. Chemoattractants or chemokines were added to
the cell solution and incubated for 30 s at 378C. 50 ml of Oregon
green–phalloidin solution (4 3 1027 M Oregon green–labeled
phalloidin, 0.5 mg/ml 1-a-lysophosphatidylcholine, 18% formal-
dehyde in PBS) was added to stain and fix the cells. Cells were
further incubated for 10 min at 378C, centrifuged, and resus-
pended in 0.3 ml of 1% paraformaldehyde solution. Mean fluo-
rescence was measured by flow cytometry.
Statistical Analysis. Analysis of variance with Bonnferroni-
Dunn posthoc test or Student’s t test was used where appropriate.
Statistical significance was determined for P , 0.05.
Results
The Affinity of a4b1 Integrins Is Upregulated Rapidly and
Transiently by FP and SDF-1a. A flow cytometry assay
was used to quantify the kinetics of sVCAM-1/Fc binding
to leukocytes after stimulation by FP, a chemoattractant, or
SDF-1a, a chemokine. U937 cells transfected with human
FP receptor (U937-FPR) were used initially because these
cells undergo an intracellular calcium flux and migrate in
response to either FP or chemokine stimulation (28). Bind-
ing of sVCAM-1/Fc and soluble nonimmune human IgG
(sIgG) to untreated U937-FPR cells was low level and
comparable (Fig. 1 A). Treatment of U937-FPR cells with
Mn21, which upregulates a4 integrin affinity (13, 29), in-
creased only sVCAM-1/Fc binding, and this increase was
abrogated by pretreatment with HP2/1, an a4 integrin
function-blocking monoclonal antibody (Fig. 1 A). Treat-
ment of U937-FPR cells with either FP or SDF-1a re-
sulted in sVCAM-1/Fc binding at 30 s, the earliest time
Figure 1. Rapid and transient upregulation of sVCAM-1/Fc binding
to a4 integrins by FP and SDF-1a. (A) U937-FPR cells were treated
with 0.5 mM Mn21 and assayed for binding of sVCAM-1/Fc or sIgG in
the presence or absence of monoclonal antibody HP2/1. One of two ex-
periments is shown (mean 6 SD, n = 3; *P , 0.05). (B) Representative
flow cytometry profiles of sVCAM-1/Fc binding 30 s after stimulation
with 0.5 mM Mn21, 100 nM FP, or 200 ng/ml SDF-1a with or without
pretreatment with PTx. Nonshaded curves are unstimulated controls. (C)
Time course of sVCAM-1/Fc binding to buffer-treated U937-FPR cells
(Control, n = 9) and cells stimulated with FP (n = 9) or SDF-1a (n = 5).
Asterisks indicate a significant difference from the corresponding control
time point (mean 6 SEM; P , 0.05). (D) A representative of three inde-
pendent time course experiments showing HUTS-21 binding to FP- or
SDF-1a–treated U937-FPR cells, expressed as the percentage of maximal
binding induced by Mn21.1152 a4 Integrin Affinity Upregulation Mediates Arrest
point tested, and was sensitive to PTx, indicating signaling
through G protein–coupled receptors (Fig. 1 B). FP and
SDF-1a induced a 48% (n = 17) and 31% (n = 14) shift in
the mean fluorescence intensity, respectively, relative to
Mn21 treatment. Upregulated sVCAM-1/Fc binding was
transient and began to decline towards baseline after 2 min
for both FP and SDF-1a (Fig. 1 C). FP treatment of vec-
tor-transfected U937 cells did not increase binding of
sVCAM-1/Fc and neither FP nor SDF-1a stimulation in-
creased binding of sIgG (data not shown). Similar results
were obtained with the monocytic cell line THP-1 (data
not shown). The above data suggest that a4 integrin affin-
ity on monocyte cell lines is constitutively low and can be
upregulated rapidly and transiently by chemoattractant or
SDF-1a stimulation.
Changes in b1 integrin affinity can also be detected by
the monoclonal antibody HUTS-21 (16). Treatment of
U937-FPR with either FP or SDF-1a resulted in a gradual
and a sustained increase in HUTS-21 binding, the magni-
tude of which was relatively modest compared with bind-
ing induced by Mn21 (Fig. 1 D). The sustained nature of
HUTS-21 binding suggests that this antibody recognizes
high affinity b1 integrins and locks or traps them in this
confirmation.
Transient Induction of a4 Integrin–mediated Adhesion to
VCAM-1 by FP and SDF-1a. The effect of FP or SDF-
1a  stimulation on a4 integrin–mediated adhesion of
U937-FPR cells to VCAM-1 was ascertained using a leu-
kocyte detachment assay (Fig. 2). At 2 min, which is the
shortest time interval that could be accurately assessed in
this assay, both stimuli induced adhesion that was inhibited
by PTx or HP2/1 pretreatment. The induction of adhesion
was transient. Maximal adhesion of U937-FPR, but not
U937 vector-transfected cells, was observed after cells were
allowed to interact with VCAM-1/Fc, coimmobilized
with FP for 2 min, and declined to baseline by 10 min (Fig.
2 A). This observation is consistent with a recent study
showing that FP stimulation of human FP receptor–trans-
fected JY cells stimulated transient a4 integrin–mediated
adhesion on VCAM-1 (30). Coimmobilized SDF-1a also
induced transient adhesion of U937-FPR cells to VCAM-
1/Fc, which was maximal at 2 min and returned to baseline
by 20 min (Fig. 2 B). The time course for induced a4 inte-
grin–mediated adhesion was similar to upregulated a4 inte-
grin affinity, determined by sVCAM-1/Fc binding in Fig.
1. The PTx-sensitive nature of FP- and SDF-1a–induced
adhesion supports the involvement of Gai proteins, consis-
tent with previous reports (31). Furthermore, the upregula-
Figure 2. Transient induction of a4 integrin–mediated adhesion to
VCAM-1 by FP and SDF-1a. Detachment assays were carried out using
U937 cells and flow chambers with the adhesion surface coated with
VCAM-1/Fc (600 molecules/mm2) with or without coimmobilized FP
or SDF-1a. At different time intervals, a fluid shear stress of 10 dyn/cm2
was applied. After 20 s of shear, the percentage of cells remaining adher-
ent in six fields (mean 6 SD) is plotted for one of three experiments.
(A) U937 vector or U937-FPR cells adhered to VCAM-1 plus FP, and
(B) U937-FPR cells adhered to VCAM-1 with or without SDF-1a. (C)
U937-FPR cells were preincubated with medium (Control), 100 ng/ml
PTx for 6 h at 378C, or 10 mg/ml monoclonal antibody HP2/1 for 15
min at 228C and adhered for 2 min to VCAM-1/Fc with or without FP
or SDF-1 before application of shear stress (mean 6 SEM, n = 4). Signif-
icant differences from control are indicated. *P , 0.005; ‡P , 0.05.
Figure 3. FP or SDF-1a coimmobilized with VCAM-1 induces arrest
and accumulation of U937-FPR cells. (A) U937-FPR cells in the pres-
ence or absence of 0.5 mM Mn21 were infused at 1.0 dyn/cm2 into paral-
lel plate flow chambers in which the adhesion surface was coated with in-
creasing densities of VCAM-1/Fc. The mean 6 SD of cells accumulated
during 2 min of flow in six independent microscopic fields is shown. (B)
Untreated or 100 ng/ml PTx-pretreated U937-FPR cells were infused
into chambers coated with VCAM-1/Fc with or without FP or SDF-1a.
For comparison, Mn21 was also included in the assay buffer. At each time
point, the mean of cells accumulated in six fields is shown for one of two
representative experiments.1153 Chan et al.
tion of U937-FPR cell adhesion to VCAM-1 by FP or
SDF-1a was diminished by a 15-min pretreatment of cells
with a high concentration of soluble FP or SDF-1a, con-
sistent with desensitization of receptors (data not shown).
A recent report suggested that fractalkine, a C-XXX-C
chemokine, can also function as an adhesion molecule (32).
Therefore, we tested whether immobilized SDF-1a alone
could mediate adhesion of U937-FPR cells. Adhesion of
U937-FPR cells was not observed when SDF-1a was
coimmobilized with nonimmune IgG rather than VCAM-1
(data not shown), which indicates that SDF-1a was not
acting as an adhesion molecule but activated a4 integrins to
mediate strong and stable binding to VCAM-1.
Coimmobilized FP or SDF-1a Induces Arrest and Accumula-
tion of Flowing U937-FPR Cells. Interactions between a4
integrins and VCAM-1 have been shown to mediate leu-
kocyte rolling in vitro (22–24) and in vivo (33). The den-
sity of VCAM-1 may have profound effects on leukocyte
adhesive interactions under shear flow, and we found that
untreated U937-FPR cells can arrest and accumulate upon
contact with a high density of VCAM-1/Fc (1,200 mole-
cules/mm2) independent of chemokine or chemoattractant
signaling (Fig. 3 A). These data are consistent with a previ-
ous report using lymphocytes (34). At 600 molecules/mm2
or lower, mostly transient tethering and rolling interactions
were observed, with limited arrest and accumulation of
leukocytes. Upregulation of a4 integrin affinity by Mn21
resulted in leukocyte arrest at much lower VCAM-1 den-
sities. We used relatively low densities of VCAM-1/Fc
(300 or 600 molecules/mm2) to test whether coimmobi-
lized FP or SDF-1a could upregulate a4 integrin/VCAM-
1–mediated arrest. Coimmobilized FP or SDF-1a induced
arrest and accumulation of U937-FPR cells (Fig. 3 B).
Leukocyte arrest occurred virtually immediately upon
contact with the adhesion surface, and rolling interactions
greater than one cell diameter were observed only rarely.
Arrest events induced by FP or SDF-1a but not Mn21
were inhibited by pretreatment of U937-FPR cells with
PTx, indicating involvement of G protein–coupled signal-
ing. FP had no effect on vector-transfected U937 cells
(data not shown).
sVCAM-1 Blocks a4 Integrin–mediated Arrest. Soluble
ligands bind high affinity integrin and inhibit high affinity
but not high avidity adhesion (12–14). Therefore, accumu-
lation assays were performed in the presence of sVCAM-1/
Fc to determine whether arrest and accumulation of flow-
ing U937-FPR cells stimulated by coimmobilized FP or
SDF-1a was dependent on very rapid upregulation of a4
integrin affinity. Fig. 4 demonstrates that accumulation of
U937-FPR cells on VCAM-1/Fc coimmobilized with FP
or SDF-1a could be inhibited by sVCAM-1/Fc. As a posi-
tive control, inclusion of Mn21 in the assay buffer resulted
in arrest of U937-FPR cells on VCAM-1–coated surfaces,
which was also blocked, although partially, by sVCAM-1/
Fc. The inability of 20 mg/ml of sVCAM-1/Fc to block
Mn21-induced cell accumulation completely is likely be-
cause of incomplete saturation of high affinity a4 integrins.
Role of the Actin Cytoskeleton. To determine whether
the upregulation of a4 integrin affinity by FP and SDF-1a
was dependent on an intact actin cytoskeleton, U937-FPR
cells were pretreated with cytD. CytD treatment did not
inhibit basal sVCAM-1/Fc binding or that induced by ei-
ther FP or SDF-1a (Fig. 5). Similar results were obtained
with latrunculin B, an inhibitor of actin polymerization for
which the mechanism of inhibition is different from cytD
(data not shown). The efficacy of cytD treatment was de-
Figure 4. FP- and SDF-1a–induced leukocyte arrest is inhibited by
sVCAM-1/Fc. U937-FPR cells incubated with 20 mg/ml of sVCAM-
1/Fc or sIgG were infused for 2 min at 1.0 dyn/cm2 into flow chambers
and allowed to accumulate on surfaces coated with VCAM-1/Fc alone
(control) or coimmobilized with FP or SDF-1a (FP or SDF-1). In each
experiment, 0.5 mM Mn21 was also included in the buffer and cell ac-
cumulation on VCAM-1/Fc was determined. Means 6 SEM of six ex-
periments and differences from the control (*P , 0.05) and from the
corresponding sIgG treatment (‡P , 0.005) are shown.
Figure 5. CytD does not inhibit FP- or SDF-1a–induced upregulation
of sVCAM-1/Fc binding. U937-FPR cells were treated with 2 mM cytD
for 15 min or buffer. Binding of sVCAM-1/Fc in the presence or absence
of FP or SDF-1a was assessed by flow cytometry at the indicated times.
Means 6 SEM of four experiments are shown.1154 a4 Integrin Affinity Upregulation Mediates Arrest
termined by measuring actin polymerization induced by
treating U937-FPR cells with FP or SDF-1a. A 30-s treat-
ment with either agent induced binding of Oregon green–
conjugated phalloidin (detected by flow cytometery),
which was abrogated by pretreatment of cells with cytD
(data not shown). Although induction of high affinity a4
integrins was not dependent on an intact cytoskeleton,
cytD treatment abolished tethering and rolling of cells on
VCAM-1–coated surfaces. These data suggest that disrup-
tion of the actin cytoskeleton may alter the distribution of
a4 integrins on the leukocyte surface, which interferes
with adhesive functions required for tethering and rolling
of cells under flow. Inhibition of tethering and rolling pre-
vents subsequent adhesive events including arrest; there-
fore, it was not possible to determine whether cytD inhibits
arrest directly.
Upregulation of a4 Integrin Affinity in Human Peripheral
Blood Monocytes. The flow cytometer assay was used to
determine whether FP or SDF-1a stimulation of human
monocytes and lymphocytes could upregulate a4 integrin
affinity. Peripheral blood mononuclear cells were isolated
by density gradient centrifugation, and sVCAM-1/Fc bind-
ing to monocytes and lymphocytes (CD32 and CD31) was
determined. Monocytes were identified by their character-
istic light scatter properties and confirmed by staining for
CD14. FP stimulated sVCAM-1/Fc binding to monocytes
but not lymphocytes (Fig. 6 A), which was consistent with
Figure 6. Upregulation of a4 integrin affinity in human blood mono-
cytes. (A) Peripheral blood monocytes and lymphocytes were isolated and
sVCAM-1/Fc binding was determined by flow cytometry 30 s after stimu-
lation with 100 nM FP or 200 ng/ml SDF-1a. For each cell type, data are
expressed as the percentage of maximal binding induced by 0.5 mM Mn21
treatment after subtracting binding to untreated cells (mean 6 SEM, n = 7;
*P , 0.05). (B) In a whole blood flow cytometry assay, antibody HP2/1
inhibited sVCAM-1/Fc binding by monocytes, which were identified by
costaining for CD14. For each treatment group, data were standardized to
sIgG binding (mean 6 SEM, n = 5). (C) Flow chamber arrest assays were
performed with monocytes purified from blood by negative depletion.
Cells were infused in a buffer containing sIgG or 20 mg/ml sVCAM-1/Fc.
During a 2-min infusion at 0.75 dyn/cm2, cells arrested and accumulated
on surfaces coated with VCAM-1/Fc alone or coimmobilized with SDF-
1a or FP (mean 6 SEM, n = 4 experiments). Significant differences from
the VCAM-1/Fc alone group (‡P , 0.005) and from the corresponding
sIgG treatment group (§P , 0.05) are shown.
Figure 7. Monocyte arrest is induced by various chemoattractants
but not chemokines. (A) Peripheral blood monocytes isolated by nega-
tive depletion were infused for 2 min at 1.0 dyn/cm2 in the presence of
sVCAM-1/Fc or sIgG (Control). The adhesion surfaces of parallel
plate flow chambers were coated with VCAM-1/Fc alone or coimmo-
bilized with a chemoattractant. SDF-1a was used as a positive control
(mean 6 SEM, n = 4 experiments). Significant differences from the
surface coated with VCAM-1/Fc alone (*P , 0.05) and from the cor-
responding sIgG treatment (‡P  , 0.05) are shown. (B) Monocytes
were infused into parallel plate flow chambers coated with VCAM-1/
Fc alone or coimmobilized with the indicated chemokine (mean 6
SEM, n = 4 experiments). Antag., antagonist.1155 Chan et al.
the expression pattern of FP receptors (35). In contrast,
SDF-1a  upregulated sVCAM-1/Fc binding to both mono-
cytes and lymphocytes, consistent with the expression of
the SDF-1a receptor CXCR4 on these cell types (36). Up-
regulated sVCAM-1/Fc binding to lymphocytes was mark-
edly weaker in comparison to monocytes, which may be
due to the heterogeneity of CD31 and CD32 cells with re-
gard to responsiveness to SDF-1a (37). A recent report
showed that increased sVCAM-1 binding was only found
in a subgroup of CD31 T lymphocytes after PMA stimula-
tion (14). An alternative possibility is that modulation of a4
integrin affinity occurs primarily in monocytes not lym-
phocytes. The specificity of FP- or SDF-1a–upregulated
sVCAM-1/Fc binding was confirmed by blocking a4 inte-
grins with HP2/1 using a whole blood assay in which
monocytes were identified by staining for CD14 (Fig. 6 B).
As with U937-FPR cells, pretreatment with cytD failed to
block sVCAM-1 binding to monocytes induced by either
FP or SDF-1a (data not shown). In the flow chamber ar-
rest assay, coimmobilization of either FP or SDF-1a with
VCAM-1 stimulated arrest and accumulation of purified
peripheral blood monocytes, which was inhibited by
sVCAM-1/Fc in the assay buffer (Fig. 6 C). As with
U937-FPR cells, peripheral blood monocytes that tethered
arrested rapidly on surfaces coated with VCAM-1 and FP
or SDF-1a. Cells that rolled for more than one cell diame-
ter before arrest were observed rarely. Occasional cells that
tethered did not arrest and were released back into the flow
stream.
We evaluated whether other chemoattractants and
chemokines can stimulate monocyte arrest when coimmo-
bilized with VCAM-1. C5a and PAF both induced arrest
of peripheral blood monocytes, which was inhibited by
sVCAM-1/Fc in the assay buffer (Fig. 7 A). Monocyte ar-
rest was not observed on surfaces coated with PAF plus
VCAM-1 when monocytes were pretreated with a PAF
antagonist (data not shown) or when the PAF antagonist
was coimmobilized with VCAM-1 (Fig. 7 A). An unex-
pected finding was that all chemokines that we coimmobi-
lized with VCAM-1 with the exception of SDF-1a did not
upregulate monocyte arrest (Fig. 7 B), although all are
known to mediate monocyte chemotaxis. MCP-1 and
RANTES induced actin polymerization in monocytes us-
ing a 30-s flow cytometer assay (data not shown).
Discussion
Previous studies demonstrated that chemokines and
chemoattractants trigger the arrest of rolling leukocytes.
For example, chemokines, including SDF-1a, induce rapid
arrest of rolling lymphocytes on recombinant ICAM-1 (7,
38), and SDF-1a and FP stimulate leukocyte arrest on re-
combinant VCAM-1 (39, 40). Integrins are thought to be
key mediators of leukocyte arrest, and our study demon-
strates that rapid upregulation of a4 integrin affinity medi-
ates chemoattractant-stimulated arrest of monocytes on
VCAM-1. Lymphocyte b2 integrin affinity can also be up-
regulated by chemokines, which mediates arrest on ICAM-
1–coated surfaces (41).
Our data clearly demonstrate that stimulation of mono-
cytes with FP or SDF-1a rapidly and transiently increases
the affinity of a4 integrins. Upregulation of a4 integrin af-
finity, as determined by sVCAM-1/Fc binding using flow
cytometry, was detected within 30 s, the earliest time that
could be accurately assessed by this assay. Actually, chemo-
kine upregulation of a4 integrin affinity likely occurs
within a second, since leukocytes arrested within this time
period after contact with coimmobilized SDF-1a or FP
and VCAM-1. We also demonstrated that the upregulation
of a4 integrin affinity is transient, returning to baseline by
10 min. This may explain why high affinity a4 integrins
were not detected in previous studies that showed in-
creased a4 integrin–mediated leukocyte adhesion after
stimulation by chemokines (13, 42, 43). Another reason
why we were able to detect chemokine-mediated changes
in a4 integrin affinity may be because we studied mono-
cytes and monocyte-like cell lines, whereas others focused
on lymphocytes. In Fig. 6, we showed that SDF-1a in-
duced only modest levels of sVCAM-1/Fc binding to lym-
phocytes compared with monocytes.
In addition to chemokines, other stimuli can upregulate
a4 integrin affinity. For example, ligation of L-selectin on
T lymphocytes results in binding of soluble fibronectin
(44). Cross-linking of cell surface molecules CD2, CD3,
CD7, or CD28 on T lymphocytes also upregulates soluble
fibronectin binding mediated by a4b1 and/or a5b1 inte-
grins (45), and phorbol ester stimulation increases sVCAM-
1/Fc binding (14). Affinity modulation has been reported
for many integrins including LFA-1, Mac-1, a5b1, and
aIIbb3 (17, 21, 46, 47), and may participate in a variety of
pathophysiological processes including rheumatoid arthri-
tis, autoimmune diabetes, and tumor invasion (48–50).
In this study, our focus was on the mechanism of
chemoattractant and chemokine-induced leukocyte arrest,
which is an early step in the emigration of leukocytes.
Chemokine signaling can also directly contribute to later
stages of leukocyte emigration, including firm adhesion and
transendothelial migration, by inducing rearrangement of
the leukocyte cytoskeleton and changes in a4 and b2 inte-
grin functions (51). Leukocyte rolling precedes arrest and is
mediated by selectin–carbohydrate and/or low affinity a4
integrin–VCAM-1 interactions. The properties of selectin-
mediated adhesion that appear to be essential for rolling
have been characterized as rapid binding and release of
ligand (52). Presumably low affinity a4 integrin–VCAM-1
bonds have similar properties since leukocytes that express
low affinity a4 integrins roll on VCAM-1. Jurkat cells,
which express high affinity a4 integrins, tether and arrest
but do not roll on VCAM-1–coated surfaces (25). This sug-
gests that high affinity a4 integrin–VCAM-1 bonds can
form rapidly (to mediate tethering) yet are stable (to medi-
ate arrest). Our experiments demonstrated that several
chemoattractants and SDF-1a presented to monocytes on
an adhesive surface can rapidly mediate arrest of cells shortly
after the initial contact. Blockade of arrest by sVCAM-1/Fc1156 a4 Integrin Affinity Upregulation Mediates Arrest
indicates that high affinity and not high avidity a4 integrins
were responsible. Blockade of a4 integrin function by anti-
body HP2/1 confirmed the role of a4 integrins.
Of all the chemokines that we tested, only SDF-1a was
able to induce monocyte arrest. SDF-1a is unique in that it
is the only chemokine that binds to CXCR4. A previous
study showed that MCP-1 and other chemokines were
able to induce monocyte arrest on human endothelium
transfected with E-selectin (6). One explanation for the ef-
fectiveness of MCP-1 in the latter model may be that liga-
tion of molecules such as L-selectin or P-selectin glycopro-
tein ligand 1 while rolling on endothelium may provide
additional signals that augment or cooperate with chemo-
kine signaling. This is not unreasonable considering that
L-selectin can signal (53), and if cross-linked, will upregu-
late T cell binding of soluble fibronectin (44)
Upregulated integrin affinity may mediate arrest alone or
in concert with upregulated avidity (clustering). The recent
study by Constantin et al. (41) suggested that both affinity
and avidity of b2 integrins are upregulated by chemokines
and contribute to the arrest of T lymphocytes. Grabovsky
at al. (43) suggested that subsecond clustering of a4 inte-
grins in response to chemokine stimulation increases teth-
ering and rolling of T lymphocytes. It is possible that up-
regulation of integrin avidity and enhanced leukocyte
tethering can lead to arrest under appropriate conditions.
Avidity-mediated adhesion requires not only clustered in-
tegrins, but also a sufficiently high density of ligand to al-
low multiple simultaneous adhesive interactions. In Fig. 3,
we showed that unactivated U937 cells arrest with a rela-
tively high frequency on surfaces coated with a high den-
sity of VCAM-1. With affinity-mediated adhesion, much
lower densities of VCAM-1 could mediate comparable ar-
rest.
Integrin interactions with the actin cytoskeleton regulate
avidity by directing clustering and lateral diffusion in the
plane of the cell membrane (54). Cytoplasmic tail deletions
of a4 integrin restrict lateral mobility and abrogate cell ad-
hesion to VCAM-1 without changing a4 integrin affinity
for soluble ligand (55). Similar deletions in both aL and b2
integrin subunits that link LFA-1 to the actin cytoskeleton
result in clustering and increased adhesion (20, 56). In these
studies, increased adhesion was not associated with upregu-
lated binding of soluble ligand, although the high affinity
neoepitope recognized by monoclonal antibody 24 was de-
tected (20). The actin cytoskeleton can regulate the affinity
of aIIbb3 integrin since treatment of unstimulated platelets
with cytD increased binding of soluble ligand (57). In our
study, cytD treatment did not significantly increase binding
of sVCAM-1 in untreated leukocytes, suggesting that the
actin cytoskeleton does not maintain a4 integrins in a low
affinity state. Furthermore, cytD and latrunculin B did not
abrogate increased sVCAM-1/Fc binding induced by ei-
ther FP or SDF-1a, suggesting that rapid upregulation of
a4 integrin affinity is independent of actin polymerization.
Emigration of leukocytes likely involves multiple and
sequential signaling events. During arrest, chemokine-
induced upregulation of a4 integrin affinity and binding to
VCAM-1 may generate outside-in signals via a4 integrins
that lead to cell spreading and upregulation of LFA-1 avid-
ity (26, 58). This may stabilize leukocyte adhesion. In turn,
LFA-1 binding to ICAM-1 can also generate outside-in
signals that downregulate a4 integrin–mediated adhesion
(59), which may facilitate leukocyte migration. High affin-
ity a4 integrins may contribute to the pathogenesis of vari-
ous inflammatory diseases. For example, the administration
of VCAM-1/Fc to mice significantly delayed the onset of
adoptively transferred autoimmune diabetes (48) and the
peptide EILDVPST, which binds to high affinity a4 inte-
grin, inhibited mononuclear cell adhesion to early athero-
sclerotic endothelium (60). Blockade of high affinity a4 in-
tegrins may provide a strategy to inhibit leukocyte
emigration and limit the initiation or progression of some
inflammatory diseases.
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